- Home
- SOAR vs GLMD Comparison
SOAR vs GLMD Comparison
Compare SOAR & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- GLMD
- Stock Information
- Founded
- SOAR 2021
- GLMD 2000
- Country
- SOAR United States
- GLMD Israel
- Employees
- SOAR N/A
- GLMD N/A
- Industry
- SOAR Blank Checks
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SOAR Finance
- GLMD Health Care
- Exchange
- SOAR Nasdaq
- GLMD Nasdaq
- Market Cap
- SOAR 3.8M
- GLMD 4.5M
- IPO Year
- SOAR N/A
- GLMD 2014
- Fundamental
- Price
- SOAR $1.63
- GLMD $1.50
- Analyst Decision
- SOAR
- GLMD
- Analyst Count
- SOAR 0
- GLMD 0
- Target Price
- SOAR N/A
- GLMD N/A
- AVG Volume (30 Days)
- SOAR 404.0K
- GLMD 2.6M
- Earning Date
- SOAR 05-14-2025
- GLMD 04-07-2025
- Dividend Yield
- SOAR N/A
- GLMD N/A
- EPS Growth
- SOAR N/A
- GLMD N/A
- EPS
- SOAR N/A
- GLMD N/A
- Revenue
- SOAR $46,288,000.00
- GLMD N/A
- Revenue This Year
- SOAR N/A
- GLMD N/A
- Revenue Next Year
- SOAR N/A
- GLMD N/A
- P/E Ratio
- SOAR N/A
- GLMD N/A
- Revenue Growth
- SOAR 97.25
- GLMD N/A
- 52 Week Low
- SOAR $1.31
- GLMD $1.33
- 52 Week High
- SOAR $90.00
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- SOAR 34.61
- GLMD 34.28
- Support Level
- SOAR $1.31
- GLMD $1.33
- Resistance Level
- SOAR $2.24
- GLMD $1.88
- Average True Range (ATR)
- SOAR 0.25
- GLMD 0.35
- MACD
- SOAR 0.08
- GLMD -0.04
- Stochastic Oscillator
- SOAR 31.07
- GLMD 7.75
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.